Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.
dc.contributor.author | Boelens, Jaap Jan | |
dc.contributor.author | Aldenhoven, Mieke | |
dc.contributor.author | Purtill, Duncan | |
dc.contributor.author | Ruggeri, Annalisa | |
dc.contributor.author | Defor, Todd | |
dc.contributor.author | Wynn, Robert | |
dc.contributor.author | Wraith, Ed | |
dc.contributor.author | Cavazzana-Calvo, Marina | |
dc.contributor.author | Rovelli, Attilio | |
dc.contributor.author | Fischer, Alain | |
dc.contributor.author | Tolar, Jakub | |
dc.contributor.author | Prasad, Vinod K | |
dc.contributor.author | Escolar, Maria | |
dc.contributor.author | Gluckman, Eliane | |
dc.contributor.author | O'Meara, Anne | |
dc.contributor.author | Orchard, Paul J | |
dc.contributor.author | Veys, Paul | |
dc.contributor.author | Eapen, Mary | |
dc.contributor.author | Kurtzberg, Joanne | |
dc.contributor.author | Rocha, Vanderson | |
dc.contributor.author | Eurocord | |
dc.contributor.author | Inborn Errors Working Party of European Blood and Marrow Transplant group | |
dc.contributor.author | Duke University Blood and Marrow Transplantation Program | |
dc.contributor.author | Centre for International Blood and Marrow Research | |
dc.date.accessioned | 2022-03-23T20:45:10Z | |
dc.date.available | 2022-03-23T20:45:10Z | |
dc.date.issued | 2013-05 | |
dc.date.updated | 2022-03-23T20:45:10Z | |
dc.description.abstract | We report transplantation outcomes of 258 children with Hurler syndrome (HS) after a myeloablative conditioning regimen from 1995 to 2007. Median age at transplant was 16.7 months and median follow-up was 57 months. The cumulative incidence of neutrophil recovery at day 60 was 91%, acute graft-versus-host disease (GVHD) (grade II-IV) at day 100 was 25%, and chronic GVHD and 5 years was 16%. Overall survival and event-free survival (EFS) at 5 years were 74% and 63%, respectively. EFS after HLA-matched sibling donor (MSD) and 6/6 matched unrelated cord blood (CB) donor were similar at 81%, 66% after 10/10 HLA-matched unrelated donor (UD), and 68% after 5/6 matched CB donor. EFS was lower after transplantation in 4/6 matched unrelated CB (UCB) (57%; P = .031) and HLA-mismatched UD (41%; P = .007). Full-donor chimerism (P = .039) and normal enzyme levels (P = .007) were higher after CB transplantation (92% and 98%, respectively) compared with the other grafts sources (69% and 59%, respectively). In conclusion, results of allogeneic transplantation for HS are encouraging, with similar EFS rates after MSD, 6/6 matched UCB, 5/6 UCB, and 10/10 matched UD. The use of mismatched UD and 4/6 matched UCB was associated with lower EFS. | |
dc.identifier | S0006-4971(20)58688-6 | |
dc.identifier.issn | 0006-4971 | |
dc.identifier.issn | 1528-0020 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | American Society of Hematology | |
dc.relation.ispartof | Blood | |
dc.relation.isversionof | 10.1182/blood-2012-09-455238 | |
dc.subject | Eurocord | |
dc.subject | Inborn Errors Working Party of European Blood and Marrow Transplant group | |
dc.subject | Duke University Blood and Marrow Transplantation Program | |
dc.subject | Centre for International Blood and Marrow Research | |
dc.subject | Hematopoietic Stem Cells | |
dc.subject | Humans | |
dc.subject | Mucopolysaccharidosis I | |
dc.subject | Myeloablative Agonists | |
dc.subject | Histocompatibility Testing | |
dc.subject | Treatment Outcome | |
dc.subject | Transplantation Conditioning | |
dc.subject | Hematopoietic Stem Cell Transplantation | |
dc.subject | Retrospective Studies | |
dc.subject | Adolescent | |
dc.subject | Child | |
dc.subject | Child, Preschool | |
dc.subject | Infant | |
dc.subject | Tissue Donors | |
dc.subject | Tissue and Organ Procurement | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Young Adult | |
dc.title | Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. | |
dc.type | Journal article | |
duke.contributor.orcid | Kurtzberg, Joanne|0000-0002-3370-0703 | |
pubs.begin-page | 3981 | |
pubs.end-page | 3987 | |
pubs.issue | 19 | |
pubs.organisational-group | Duke | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Faculty | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Pathology | |
pubs.organisational-group | Pediatrics | |
pubs.organisational-group | Pediatrics, Hematology-Oncology | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Institutes and Provost's Academic Units | |
pubs.organisational-group | Initiatives | |
pubs.organisational-group | Duke Innovation & Entrepreneurship | |
pubs.organisational-group | Pediatrics, Transplant and Cellular Therapy | |
pubs.publication-status | Published | |
pubs.volume | 121 |
Files
Original bundle
- Name:
- p263 Boelens.pdf
- Size:
- 666.47 KB
- Format:
- Adobe Portable Document Format
- Description:
- Published version